Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK042 in Advanced Solid Tumors
NCT06773091Phase 1Recruiting
- Sponsor
- Shanghai Enkai Cell Technology
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NK042 in solid tumor (advanced stage), sponsored by Shanghai Enkai Cell Technology. Primary endpoints: Incidence of Adverse events (AEs) and Serious Adverse Events (SAEs) up to 1 year, Dose Limiting Toxicities up to 28 days and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
NK042
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06773091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06773091.